Trends in HLA antibody screening and identification and their role in transplantation

Expert Review of Clinical Immunology

Volumn 4, Issue 3, 2008, Pages 391-399

  Murphey, Cathi L ^a   Forsthuber, Thomas G ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

HLA; HLA antibody; Human leukocyte antigen; Major histocompatability complex; MHC; Transplantion

Indexed keywords

ALLOANTIBODY; HLA ANTIBODY; HLA ANTIGEN;

ANTIBODY BLOOD LEVEL; ANTIBODY SCREENING; ANTIGEN ANTIBODY REACTION; CADAVER DONOR; CELL ASSAY; CELL TRANSFORMATION; COST EFFECTIVENESS ANALYSIS; FLOW CYTOMETRY; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HLA MATCHING; HUMAN; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; LYMPHOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; ORGAN TRANSPLANTATION; PATIENT SELECTION; REVIEW;

EID: 46249087570     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.4.3.391     Document Type: Review

References (52)

1. Cecka JM. The UNOS Scientific Renal Transplant Registry. Clin. Transpl. 1-14 (1996).
2. Takemoto SK, Terasaki PI, Gjertson DW, Cecka JM. Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N. Engl. J. Med. 343(15), 1078-1084 (2000).
3. Gjertson DW, Terasaki PI, Takemoto S, Mickey MR. National allocation of cadaveric kidneys by HLA matching. Projected effect on outcome and costs. N. Engl. J. Med. 324(15), 1032-1036 (1991).
4. Terasaki PI, Cho Y, Takemoto S, Cecka M, Gjertson D. Twenty-year follow-up on the effect of HLA matching on kidney transplant survival and prediction of future twenty-year survival. Tansplant. Proc. 28(3), 1144-1145 (1996).
5. Beatty PG, Mori M, Milford E. Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. Transplantation 60, 778-783 (1995)
6. Roberts JP, Wolfe RA, Bragg-Gresham JL et al. Effect of changing the priority for HLA matching on the rates and outcomes of kidney transplantation in minority groups. N. Engl. J. Med. 350(6), 545-551 (2004).
7. Doxiadis II, de Fijter JW, Mallat MJ et al. Simpler and equitable allocation of kidneys from postmortem donors primarily based on full HLA-DR compatibility. Transplantation 83(9), 1207-1213 (2007).
8. Patel, R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N. Engl. J. Med. 280, 735-739 (1969).
9. Gebel HM, Bray RA. Sensitization and sensitivity: defining the unsensitized patient. Transplantation 69(7), 1370-1374 (2000).
10. Karpinski M, Rush D, Jeffery J et al. Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J. Am. Soc. Nephrol. 12(12), 2807-2814 (2001).
11. Bray RA, Nickerson PW, Kerman RH, Gebel HM. Evolution of HLA antibody detection: technology emulating biology. Immunol. Res. 29(1-3), 41-54 (2004).
12. Ting A, Terasaki PI. Lymphoctye-dependent antibody cross-matching for transplant patients. Lancet 1(7902), 304-306 (1975).
13. Fuller TC, Phelan D, Gebel HM, Rodey GE. Antigenic specificity of antibody reactive in the antiglobulin-augmented lymphocytotoxicity test. Transplantation 34(1), 24-29 (1982).
14. Kerman RH, Kimball PM, Van Buren CT et al. AHG and DTE/AHG procedure identification of crossmatch-appropriate donor-recipient pairings that result in improved graft survival. Transplantation 51(2), 316-320 (1991).
15. Sayeh MH. Why do we reject a graft? Role of indirect allo-recognition in graft rejection. Kidney Int. 56, 1967-1979 (1999).
16. Jeannet M, Pinn VW, Flax MH, Winn HJ, Russell PS. Humoral antibodies in renal allotransplantation in man. N. Engl. J. Med. 282, 111-117 (1970).
17. Gould DS, Auchincloss H Jr. Direct and indirect recognition: the role of MHC antigens in graft rejection. Immunol. Today 20(2), 77-82 (1999).
18. Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 7465, 662-665 (1966).
19. Akalin E, Watschinger B. Antibody-mediated rejection. Semin. Nephrol. 27(4), 393-407 (2007).
20. Bryan CF, Martinez J, Muruve N et al. IgM antibodies identified by a DTT-ameliorated positive crossmatch do not influence renal graft outcome but the strength of the IgM lymphocytotoxicity is associated with DR phenotype. Clin. Transplant. 15(Suppl. 6), 28-35 (2001).
21. Barger B, Shroyer TW, Hudson SL et al. Successful renal allografts in recipients with crossmatch-positive, dithioerythritol-treated negative sera. Race, transplant history, and HLA-DR1 phenotype. Transplantation 47(2), 240-245 (1989).
22. McCalmon RT Jr, Tardif GN, Sheehan MA, Fitting K, Kortz W, Kam I. IgM antibodies in renal transplantation. Clin. Transplant. 11(6), 558-564 (1997).
23. Roden DL, van Bree J, Witvliet MD et al. IgG antibodies against an HLA antigen are associated with activated cytotoxic T cells against this antigen, IgM are not. Trasplantation 57(9), 1388-1392 (1994).
24. Pei R, Wang G, Tarsitani C et al. Simultaneous HLA class I and class II antibodies screening with flow cytometry. Hum. Immunol. 5, 313-322 (1998).
25. Connolly JK, Dyer PA, Martin S, Parrott NR, Pearson RC, Johnson RW. Importance of minimizing HLA-DR mismatch and cold preservation time in cadaveric renal transplantation. Transplantation 61(5), 709-714 (1996).
26. Lee CM, Carter JT, Randall HB et al. The effect of age and prolonged cold ischemia times on the national allocation of cadaveric renal allografts. J. Surg. Res. 91(1), 83-88 (2000).
27. Figueiredo A, Moreira P, Parada B et al. Risk factors for delayed renal graft function and their impact on renal transplantation outcome. Transplant Proc. 39(8), 2473-2475 (2007).
28. Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antibody specificities. Transplantation 75, 43-49 (2003).
29. Arnold ML, Pei R, Spriewald B, Wassmuth R. Anti-HLA class II antibodies in kidney retransplant patients. Tissue Antigens 65(4), 370-378 (2005).
30. Mizutani K, Terasaki P, Rosen A et al. Serial ten-year fbIlow-up of HLA and MICA antibody production prior to kidney graft failure. Am. J. Transplant. 5(9), 2265-2272 (2005).
31. Langan LL, Park LP, Hughes TL et al. Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am. J. Transplant. 7(4), 847-856 (2007).
32. Pollinger HS, Stegall MD, Gloor JM et al. Kidney transplantation in patients with antibodies against donor HLA class II. Am. J. transplant. 7, 857-863 (2007).
33. Schreuder GM, Hurley CKC, Marsh SG et al. The HLA dictionary 1999: a summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR and -DQ antigens. Tissue Antigens 54(4), 409-437 (1999).
34. Bodmer JG, Marsh SG, Albert ED et al. Nomenclature for factors of the HLA system, 1994. Tissue Antigens 44(1), 1-18 (1994).
35. Zachary AA, Braun WE. Calculation of a predictive value for transplantation. Transplantation 39, 316-318 (1985).
36. Zachary AA, Steinberg AF. Statistical analysis and applications of HLA population data. In: Manual of Clinical Laboratory Immunology (5th Edition). Rose NR, de Marcario EC, Folds JD, Lane HC, Nakamura RM (Eds). ASM Press, Washington, DC, USA 132-140 (1997).
37. Doxiadis II, De Meester J, Smits JM et al. The impact of special programs for kidney transplantation of highly sensitized patients in Eurotransplant. Clin. Tanspl. 115-120 (1998).
38. Claas FH, van Rood JJ. The hyperimmunized patient: from sensitization toward transplantation. Transpl. Int. 1(2), 53-57 (1988).
39. Claas FH, van Leeuwen A, van Rood JJ. Hyperimmunized patients do not need to wait for an HLA identical donor. Tissue Antigens 34(1), 23-29 (1989).
40. Bray RA, Nolen JD, Larsen C et al. Transplanting the highly sensitized patient: The Emory Algorithm. Am. J. Transplant. 6(10), 2307-2315 (2006).
41. Bielmann D, Hönger G, Lutz D, Mihatsch MJ, Steiger J, Schaub S. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am. J. Transplant. 7(3), 626-632 (2007).
42. Leffell MS, Montgomery RA, Zachary AA. The changing role of antibody testing in transplantation. Clin. Tanspl. 259-271 (2005).
43. Zangwill S, Ellis T, Stendahl G, Zahn A, Berger S, Tweddell J. Practical application of the virtual crossmatch Pediatr. Transplant. 11(6), 650-654 (2007).
44. Satoskar AA, Lehman AM, Nadasdy GM et al. Peritubular capillary C4d staining in late acute renal allograft rejection - is it relevant? Clin. Transplant. 22(1), 61-67 (2008).
45. Kawamura N, Tomita M, Hasegawa M et al. Complement C4d deposition in transplanted kidneys: preliminary report on long-term graft survival. Clin. Transplant. 19(Suppl. 14), 27-31 (2005).
46. Lefaucheur C, Nochy D, Hill GS et al. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am. J. Transplant. 7(4), 832-841 (2007).
47. Cai J, Terasaki PI. Humoral theory of transplantation: mechanism, prevention, and treatment. Hum. Immunol. 66(4), 334-342 (2005).
48. Schönemann C, Lachmann N, Kiesewetter H, Salama A. Flow cytometric detection of complement-activating HLA antibodies. Cytometry B Clin. Cytom. 62(1), 39-45 (2004).
49. Bartel G, Vahrmann M, Exner M et al. In vitro detection of C4d-fixing HLA alloantibodies: associations with capillary C4d deposition in kidney allografts. Am. j. Transplant. 8(1), 41-49 (2008).
50. Smith JD, Hamour IM, Banner NR, Rose ML. C4d fixing, luminex binding antibodies a new tool for prediction of graft failure after heart transplantation. Am. J. Transplant. 7(12), 2809-2815 (2007).
51. Zou Y, Stastny P, Süsal C, Döhler B, Opelz G. Antibodies against MICA antigens and kidney-transplant rejection. N. Engl. J. Med. 357(13), 1293-1300 (2007).
52. Mizutani K, Terasaki P, Bignon JD et al. Association of kidney transplant failure and antibodies against MICA. Hum. Immunol. 67(9), 683-691 (2006).